$26,000 was saved over 3 months when this health system implemented change on how ENA panels were ordered (could only be obtained if ANA +); intervention aimed at inappropriate testing by ortho, IM, family med and neuro abst#0058 #ACR22 @rheumnow https://t.co/GoDHat6N3v

• Health System Improvement in Inpatient ANA and Serologic Test Utilization - ACR…

"Do patients care/look for telehealth in 2022?" Ben Nowell states patients have supported telehealth for access, convenience, and affordability (gas, parking, etc.) 60% of pts still like these visits. Are you doing telemed #ACR22? @RheumNow https://t.co/5fAHsp2kBD

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Lab Domains: LAC not always feasible to recheck aCL, aB2GP IgG higher risk, higher titers (>40U) @RheumNow https://t.co/rcQaqrtDN5

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Obstetric domain redefined Added: ⭐️Cardiac thickening/vegetation ⭐️Thrombocytopenia @Rheumnow https://t.co/Me2jrnvalU

13S150. Draft ACR/EULAR APLS Classif Criteria #ACR22 Novel Aspects Macrovascular Domains - Venous and Arterial by Low and High VTE, CVD risk profiles Microvasc - Suspected/Established @RheumNow https://t.co/M8NWRSyH4p

Guan et al. Accuracy of financial disclosures in rheumatology journals. 76% papers >=1 inaccuracy. 78% authors >= undisclosed/underreported COI. Worse in clinical trials 85% @RheumNow #ACR22 Abstr#1267 https://t.co/dmqp3sj11f https://t.co/UXQgUCcGWb

• Accuracy of Financial Disclosures in American-Based Rheumatology Journals - ACR…

Frailty in Vasculitis Dr. Patricia Harkins sits down with Professor Sebastian Sattui to discuss Abstract 0444, Prevalence of Frailty and Associated Factors in Patients with Vasculitis, being presented on Saturday at #ACR22 Convergence. https://t.co/aMpcBhT5yE https://t.co/rPgA19dT0W

• https://bit.ly/3DVtSGQ

Henry @EBRheum et al. Less than 1 in 6 recommendations from ACR/EULAR informed by comparative effectiveness RCT. Many receive strong recommendation despite low/very low LOE. @RheumNow #ACR22 Abstr#1284 https://t.co/1MUM8qiwDl https://t.co/KJcf7rBQAU

• Comparative Effectiveness Randomized Controlled Trials in Rheumatology Guidelin…

Sattui @SattuiSEMD Treatment patterns in US in 26,102 PMR patients from RISE. Over 24 months <3% used IL6i, 36% DMARD. DM and morbid obese more likely to use. Women, older, and using IL6i/DMARD more likely to have GC>1 year @RheumNow #ACR22 Abstr#1546 https://t.co/Imjsgyo49j https://t.co/8E5Rj5d7Pz

• Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the…